Contactin-2 was recently identified as an autoantigen targeted by T-cells and autoantibodies in multiple sclerosis (MS). Here we analyzed the frequency of antibodies to contactin-2 (contactin-2-ab) by a cell-based assay in the serum from 105 MS patients and at least 5 years of follow-up (19 clinically isolated syndromes, 51 relapsing-remitting, 20 secondary-progressive, and 15 primary-progressive). Contactin-2-ab were detected in 4 (7.8%) relapsing-remitting patients. Clinical and magnetic resonance imaging characteristics were not significantly different from the rest of relapsing-remitting patients. In conclusion, contactin-2-ab are identified in a minority of MS patients but their presence is not associated with a particular clinicalradiological profile.
a b s t r a c t a r t i c l e i n f o
Introduction
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with both clinical and pathological heterogeneity. In the past few years, the concept of disease suggesting that T-cell-mediated immunity is sufficient for full expression of MS has been challenged, and it is now evident that B cells and humoral immune mechanisms also play key roles (Lassmann et al., 2007; Breij et al., 2008; Franciotta et al., 2008; Hauser et al., 2008; Weiner, 2009) .
Pathological studies suggest that antibodies might contribute to plaque initiation and ongoing demyelination in MS patients with established disease (Breij et al., 2008) . Although a wide range of candidate antigens and autoantibodies have been reported, the true relevance remains uncertain (Reindl et al., 2006; Racke, 2008) . Recently, contactin-2 (and its rodent orthologue, transiently expressed axonal glycoprotein 1, TAG-1), expressed in the juxtaparanodal region of myelinated axons, was identified as an autoantigen targeted by T-cells and autoantibodies. Passive transfer of contactin-2-specific T-cells induced an experimental autoimmune encephalomyelitis (EAE) with preferential inflammation of gray matter (Derfuss et al., 2009) . In that study, only a minority of antibodies to contactin-2 (contactin-2-ab) bound to the surface of the protein, a prerequisite to mediate a pathological effect, and a clinical-immunological correlation was not done. The aim of the present study was to analyze the frequency and clinical significance of antibodies to surface epitopes of contactin-2 using a sensitive cell-based assay in a larger series of patients with MS.
Patients and methods

Patients
We selected serum samples from 105 clinically definite MS patients (Poser et al., 1983) , 40 of them with paired serum/CSF samples, and at least 5 years of follow-up [at the time of sample collection the clinical syndromes were as follows: clinically isolated syndrome (19 patients), relapsing-remitting MS (51), secondary-progressive MS (20), and primary progressive MS (15)]. Patients are routinely included in a database and followed every 3-6 months. Information on clinical relapses, disability (EDSS [Expanded Disability Status Scale]) and therapies are registered prospectively as previously reported (Llufriu et al., 2010) . Demographics, clinical, and brain magnetic resonance imaging (MRI) characteristics of the patients at the time of sampling were reviewed blinded to the antibody results. As controls, we included serum samples from 20 healthy donors. The study was approved by the Ethics Committee of the Hospital Clinic and an informed consent was previously obtained.
Cell-based assay
The presence of contactin-2-ab was analyzed by indirect immunofluorescence on HEK293 cells transfected with a plasmid containing human contactin-2 cDNA clone (Homo sapiens contactin 2, axonal, Journal of Neuroimmunology 244 (2012) 103-106 
